Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

Published on Jan 25, 2021in Clinical & Translational Oncology2.737
· DOI :10.1007/S12094-021-02553-5
Gianluca Ingrosso13
Estimated H-index: 13
(University of Perugia),
Beatrice Detti20
Estimated H-index: 20
(UniFI: University of Florence)
+ 16 AuthorsMaurizio Valeriani17
Estimated H-index: 17
(Sapienza University of Rome)
OBJECTIVES To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT). PATIENTS AND METHODS Retrospective multi-institutional analysis of mCRPC patients treated with SBRT to oligoprogressive lesions during ARTT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PFS) and overall survival (OS). Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Survival analysis was performed using the Kaplan-Meier method, univariate and multivariate analysis (MVA) were performed. RESULTS Data from 34 patients were analyzed. Median NEST-free survival, r-PFS, and OS were 16.97, 13.47, and 38.3 months, respectively. At MVA, factors associated with worse NEST-free survival and r-PFS were polymetastatic burden at diagnosis of metastatic hormone-sensitive disease (hazard ratio [HR] 3.66, p = 0.009; HR 3.03, p = 0.034), PSA ≤ 7 ng/ml at mCRPC diagnosis (HR 0.23, p = 0.017; HR 0.19, p = 0.006) and PSADT ≤ 3 months at mCRPC diagnosis (HR 3.39, p = 0.026; HR 2.79, p = 0.037). Polymetastatic state at mHSPC diagnosis was associated with a decreased OS (HR 4.68, p = 0.029). No patient developed acute or late grade ≥ 2 toxicity. CONCLUSION Our results suggest that SBRT in oligoprogressive mCPRC is safe, effective and seems to prolong the efficacy of the ongoing systemic treatment positively affecting disease progression. Prospective trials are needed.
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 6
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 73
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 9 authors...
Abstract In metastatic castration-refractory prostate cancer (mCRPC), state-of-the-art treatment consists of androgen biosynthesis inhibition (abiraterone), inhibition of the androgen receptor (enzalutamide), chemotherapy, or radium-223 in combination with androgen deprivation therapy (ADT). A subgroup of these patients show oligoprogression, with the progression of only a limited number of metastatic spots, while all other metastases remain controlled by ongoing systemic therapy. In a bi-instit...
13 CitationsSource
Radium-223 (Ra-223) is a targeted alpha therapy that has been shown to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. However, prognosis after Ra-223 administration varies among patients. The aim of the present study was to assess risk factors associated with the poor prognosis of patients treated with Ra-223. We retrospectively reviewed patients’ records of treatment with Ra-223 between October 2016 and December 2019....
1 CitationsSource
#1Rosario MazzolaH-Index: 19
#2Giulio Francolini (UniFI: University of Florence)H-Index: 13
Last. Filippo Alongi (UniFI: University of Florence)H-Index: 1
view all 10 authors...
Abstract Background The present analysis aims to compare the impact of 18F-Choline and 68Ga-PSMA PET-CT guided metastases-directed therapies (MDT) in castration-sensitive oligorecurrent prostate cancer (PC) patients. Material/methods Inclusion criteria were: i) histologically-proven prostate adenocarcinoma, ii) evidence of biochemical relapse after primary tumor treatment, iii) ≤3 hypermetabolic oligorecurrent lesions detected by 18F-Choline or 68Ga-PSMA PET-CT, iv) PET-CT imaging performed in a...
8 CitationsSource
#1Matthew P. Deek (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 8
#2Kekoa Taparra (Mayo Clinic)H-Index: 10
Last. Bradley J. Stish (Mayo Clinic)H-Index: 10
view all 19 authors...
Abstract Background Available therapies for castrate-resistant prostate cancer (CRPC) confer minimal survival advantage; thus, there is interest in metastasis-directed therapy (MDT) for oligometastatic or oligoprogressive disease to improve outcomes. Here, we describe outcomes of oligoprogressive CRPC treated with stereotactic ablative radiotherapy (SABR). Objective To report outcomes of oligoprogressive CRPC treated with MDT using SABR. Design, setting, and participants Patients with oligoprogr...
6 CitationsSource
#1David A. Palma (London Health Sciences Centre)H-Index: 55
#2Robert OlsonH-Index: 46
Last. Suresh Senan (VU: VU University Amsterdam)H-Index: 86
view all 24 authors...
PURPOSEThe oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. Howev...
76 CitationsSource
#1Ryan Phillips (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 7
#2William Shi (Stanford University)H-Index: 11
Last. Phuoc T. Tran (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 50
view all 26 authors...
Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine if stereotactic ablative radiotherapy (SABR) improves oncologic outcomes in men with oligometastatic prostate cancer. Design, Setting, and Participants The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) phase 2 randomized study accrued participants from 3 US radiation tr...
117 CitationsSource
#1C. Leigh Moyer (Johns Hopkins University)H-Index: 2
#2Ryan Phillips (Johns Hopkins University)H-Index: 7
Last. Phuoc T. Tran (Johns Hopkins University)H-Index: 50
view all 18 authors...
Purpose Local ablative treatment to oligometastatic patients can result in long-term disease-free survival in some cancer patients. The importance of this treatment paradigm in prostate cancer is a rapidly evolving field. Herein, we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative stereotactic ablative radiation (SABR).
14 CitationsSource
#1Maurizio ValerianiH-Index: 17
#2Luca MarinelliH-Index: 5
Last. Mattia Falchetto OstiH-Index: 25
view all 9 authors...
Some patients experience oligo-progression during androgen receptor targeted therapy (ARTT) treatments. This progression might not indicate a real systemic drug resistance, but a selective monoclonal resistance. With the aim to delay the start of new line treatments we treated oligo-progressive sites with radiotherapy. From June 2011 to Febrary 2019, 29 consecutive metastatic castration resistant prostate cancer (mCRPC) patients were submitted to radiotherapy for oligo-progression (1–3 sites) du...
9 CitationsSource
#1Soichiro Yoshida (Tokyo Medical and Dental University)H-Index: 29
#2Taro Takahara (Tokai University)H-Index: 27
Last. Yasuhisa Fujii (Tokyo Medical and Dental University)H-Index: 49
view all 15 authors...
Purpose Locoregional therapy for oligometastatic prostate cancer has generated great interest. However, its benefit for castration-resistant prostate cancer (CRPC) has not been fully demonstrated. Our objective was to evaluate the treatment outcome of progressive site-directed therapy (PSDT) for oligoprogressive CRPC (OP-CRPC). Methods and Materials This study cohort consisted of 101 patients with CRPC who underwent whole-body diffusion-weighted magnetic resonance imaging between 2014 and 2018, ...
18 CitationsSource
#1Yoshiyuki Miyazawa (Gunma University)H-Index: 8
#2Yoshitaka Sekine (Gunma University)H-Index: 15
Last. Kazuhiro Suzuki (Gunma University)H-Index: 38
view all 14 authors...
BACKGROUND: Recent studies have shown that an early prostate-specific antigen (PSA) response to androgen receptor-targeting agents in metastatic castration-resistant prostate cancer (mCRPC) is associated with a better prognosis. We analyzed the early PSA response to enzalutamide (ENZ) by measuring the PSA doubling time (PSADT) and PSA velocity (PSAV) while monitoring oncologic outcomes and survival in Japanese patients. METHODS: We analyzed a total of 241 patients with mCRPC who were treated wit...
15 CitationsSource
Cited By1
#1Cem Onal (Başkent University)H-Index: 18
#2Gokhan Ozyigit (Hacettepe University)H-Index: 19
Last. Fadil Akyol (Hacettepe University)H-Index: 18
view all 7 authors...
PURPOSE We assessed the outcomes of stereotactic body radiotherapy (SBRT) to treat oligoprogressive castration-resistant prostate cancer (CRPC) patients with ≤5 lesions using gallium prostate-specific membrane antigen-positron emission tomography (68Ga-PSMA-PET/CT). METHODS The clinical data of 67 CRPC patients with 133 lesions treated with 68Ga-PSMA-PET/CT-based SBRT were retrospectively analyzed. All of the patients had oligoprogressive disease during androgen-deprivation therapy (ADT). The pr...